UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 157

Sortiert nach

Biomarkers and clinical trials in ALS

Journal of the neurological sciences, 2023-12, Vol.455, p.120979, Article 120979

Genge, Angela

2023

Link zum Volltext

Verfügbarkeit prüfen

Rate of speech decline in individuals with amyotrophic lateral sclerosis

Scientific reports, 2022-09, Vol.12 (1), p.15713-15713, Article 15713

2022

Link zum Volltext

Verfügbarkeit prüfen

Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States

PloS one, 2022-06, Vol.17 (6), p.e0269154-e0269154

2022

Link zum Volltext

Verfügbarkeit prüfen

Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis

International journal of molecular sciences, 2023-03, Vol.24 (6), p.5065

2023

Link zum Volltext

Verfügbarkeit prüfen

A Road Map for Remote Digital Health Technology for Motor Neuron Disease

Journal of medical Internet research, 2021-09, Vol.23 (9), p.e28766-e28766

2021

Link zum Volltext

Verfügbarkeit prüfen

Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging study

NeuroImage clinical, 2024, Vol.43, p.103633, Article 103633

2024

Link zum Volltext

Verfügbarkeit prüfen

Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study

Neurology. Genetics, 2021-12, Vol.7 (6), p.e623-e623

2021

Link zum Volltext

Verfügbarkeit prüfen

Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio Syndrome

PM & R, 2015-07, Vol.7 (7), p.677-684

2015

Link zum Volltext

Verfügbarkeit prüfen

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

The New England journal of medicine, 2022-09, Vol.387 (12), p.1099-1110

2022

Link zum Volltext

Verfügbarkeit prüfen

A Pilot Study of Regular Home Use of Deep Lung Insufflation in Neuromuscular Patients With Mild to Moderate Restrictive Impairment

Chest, 2011-10, Vol.140 (4), p.687A-687A

2011

Link zum Volltext

Verfügbarkeit prüfen

Feasibility of DBS screening to identify adult patients with Pompe disease in a neuromuscular clinic population

BMC musculoskeletal disorders, 2013-05, Vol.14 (S2), p.P1-P1, Article P1

Genge, Angela

2013

Link zum Volltext

Verfügbarkeit prüfen

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Journal of the neurological sciences, 2023-12, Vol.455, p.121088, Article 121088

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

The New England journal of medicine, 2020-07, Vol.383 (2), p.109-119

2020

Link zum Volltext

Verfügbarkeit prüfen

QRL-201-01: A multi-center, randomized, double-blind, placebo-controlled multiple ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis

Journal of the neurological sciences, 2023-12, Vol.455, p.122738, Article 122738

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

Journal of the neurological sciences, 2023-12, Vol.455, p.121718, Article 121718

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the safety, tolerability, and pharmacokinetics of QRL-101 in two phase 1 studies: QRL-101-01 in healthy adults and QRL-101-02 in adults with ALS

Journal of the neurological sciences, 2023-12, Vol.455, p.122737, Article 122737

2023

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis

Journal of the neurological sciences, 2023-12, Vol.455, p.122025, Article 122025

2023

Link zum Volltext

Verfügbarkeit prüfen

A Preliminary Videofluoroscopic Investigation of Swallowing Physiology and Function in Individuals with Oculopharyngeal Muscular Dystrophy (OPMD)

Dysphagia, 2018-12, Vol.33 (6), p.789-802

2018

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch

Drugs in R&D, 2022-09, Vol.22 (3), p.205-211

2022

Link zum Volltext

Verfügbarkeit prüfen

Validating Automatic Diadochokinesis Analysis Methods across Dysarthria Severity and Syllable Task in Amyotrophic Lateral Sclerosis

Journal of speech, language, and hearing research, 2022-03, Vol.65 (3), p.940-953

2022

Link zum Volltext

Verfügbarkeit prüfen

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48weeks of treatment

Muscle & nerve, 2023-02, Vol.67 (2), p.124-129

2023

Link zum Volltext

Verfügbarkeit prüfen

The value of testing for ATXN2 intermediate repeat expansions in routine clinical practice for amyotrophic lateral sclerosis

European journal of human genetics : EJHG, 2022-11, Vol.30 (11), p.1205-1207

2022

Link zum Volltext

Verfügbarkeit prüfen

Restoring Protein Levels With QRL-201 Has Potential to Stabilize Disease Progression in ALS: Angela Genge, MD, FRCPC, eMBA

Neurology live (Print), 2023-04

Genge, Angela

2023

Link zum Volltext

Verfügbarkeit prüfen

Rare-variant and polygenic analyses of amyotrophic lateral sclerosis in the French-Canadian genome

Genetics in medicine, 2024-01, Vol.26 (1), p.100967, Article 100967

2024

Link zum Volltext

Verfügbarkeit prüfen

Hair Product Artifact in Magnetic Resonance Imaging

Magnetic resonance imaging, 2017-01, Vol.35, p.1-3

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 157

Suche als RSS-Feed

Aktive Filter

PublikationsformBücher

PublikationsformReviews

ThemaNeurosciences & Neurology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(156)

Publikationsform

Buchkapitel
(112)
Artikel
(45)

Sprache

Englisch
(157)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Amyotrophic Lateral Sclerosis
(16)
Arts & Humanities
(14)
Humans
(14)
Life Sciences & Biomedicine
(14)
Male
(7)
Middle Aged
(7)
Female
(6)
Clinical Trials
(5)
Genetics
(4)
Magnetic Resonance Imaging
(4)
Neurology
(4)
Patients
(4)
Adult
(3)
Amyotrophic Lateral Sclerosis - Drug Therapy
(3)
Amyotrophic Lateral Sclerosis - Genetics
(3)
Double-Blind Method
(3)
General & Internal Medicine
(3)
Medicine, General & Internal
(3)
Mri
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Biomarkers and clinical trials in ALS

Rate of speech decline in individuals with amyotrophic lateral sclerosis

Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States

Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis

A Road Map for Remote Digital Health Technology for Motor Neuron Disease

Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging study

Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study

Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio Syndrome

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

A Pilot Study of Regular Home Use of Deep Lung Insufflation in Neuromuscular Patients With Mild to Moderate Restrictive Impairment

Feasibility of DBS screening to identify adult patients with Pompe disease in a neuromuscular clinic population

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

QRL-201-01: A multi-center, randomized, double-blind, placebo-controlled multiple ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

Evaluating the safety, tolerability, and pharmacokinetics of QRL-101 in two phase 1 studies: QRL-101-01 in healthy adults and QRL-101-02 in adults with ALS

Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis

A Preliminary Videofluoroscopic Investigation of Swallowing Physiology and Function in Individuals with Oculopharyngeal Muscular Dystrophy (OPMD)

Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch

Validating Automatic Diadochokinesis Analysis Methods across Dysarthria Severity and Syllable Task in Amyotrophic Lateral Sclerosis

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48weeks of treatment

The value of testing for ATXN2 intermediate repeat expansions in routine clinical practice for amyotrophic lateral sclerosis

Restoring Protein Levels With QRL-201 Has Potential to Stabilize Disease Progression in ALS: Angela Genge, MD, FRCPC, eMBA

Rare-variant and polygenic analyses of amyotrophic lateral sclerosis in the French-Canadian genome

Hair Product Artifact in Magnetic Resonance Imaging

Aktive Filter

Suchergebnisse filtern